drugset / Trial / NCT05509985
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
Phase 1
Unknown
100 enrolled
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced solid tumors.
Timeline
- Start
- 2023-08-09
- Primary completion
- 2023-09-09
- Completion
- 2024-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKG315 | Unknown | 3 mg | Intravenous |
| Subject | ASKG315 | Unknown | 45 mg | Intravenous |